CHARLES JENNISCH: Open Payments
NPI 1225133606 · URBANDALE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$178,246 in 211 payments from 6 companies in 2025. Trend: 2023 $220,248 · 2024 $148,730 · 2025 $178,246
Speaker / faculty: $142,757Consulting: $17,849Travel & lodging: $13,893Food & beverage: $3,748
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 78 | $84,975 |
| Neurocrine BioSciences, Inc. | 82 | $55,051 |
| E.R. Squibb & Sons, L.L.C. | 47 | $38,138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| ABBVIE INC. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: REXULTI, INGREZZA, COBENFY, CAPLYTA, VRAYLAR, SPRAVATO.
Industry payments across IA — which companies pay providers there.
